Vectura Group Share Price (VEC)

0.00 0.00 (0.00%) delayed: 2:14AM GMT
Bid price 0.00 Open price 0.00
Ask price 0.00 Prev close 122.00
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index n/a

Vectura Group Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) -0.13
Market Capitalisation (£m) 480.94 Gross Gearing (%) 26.40
Shares in issue (m) 402.46 Debt Ratio 22.10
P/E Ratio -170.71 Debt-to-Equity Ratio 0.79
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.36
Dividend Yield (%) 0.00 Price to book value 2.12
Dividend cover (x) 0.00 ROCE -0.03
Earning per share (p) -0.70 EPS Growth (%) 61.11
52 week high / low 171.50 / 101.00 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
08/07/2014 BUY Dr Christopher Blackwell CEO 1,212
08/07/2014 BUY Dr Trevor Phillips ED 1,212
08/07/2014 BUY Paul Oliver RES 1,212
02/07/2014 EXR John Brown NED 238,989
02/07/2014 SEXR John Brown NED 159,100

More Vectura Group Director Deals >>

Vectura Group Company News

11:04 19/11/2014

Vectura granted approval for inhaler

Vectura Group has confirmed that its partner, Sandoz, has been granted marketing authorisation by the regulatory authorities in Ireland and the Czech Republic for AirFluSal®Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). The...

11:00 19/11/2014

Czech and Irish Approval for AirFluSal Forspiro

/* */ RNS Number : 4389X Vectura Group plc 19 November 2014        Vectura Group plc   Approval in Ireland and Czech Republic for innovative respiratory inhaler AirFluSal ® Forspiro ®    ...

13:49 18/11/2014

Vectura upgraded by Investec

Investec has upgraded its recommendation on respiratory disease treatment specialist Vectura (LON:VEC) to ‘buy’ from ‘hold’ on the back of today’s interims, which it stated were largely in line with consensus. The broker said: “With assets set to be filed by partner Novartis in Q4 2014, we think...

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

5 days ago


Powered by IST's

Register now for FREE Vectura Group share price discussions